Cellumen is spinning off a unit to work on personalised medicine:
"Cellumen's successful application of Cellular Systems Biology (CSB(TM)) to drug discovery, drug development and personalized medicine over the last three years has yielded strong interest across each of these application areas," stated D. Lansing Taylor, Ph.D., CEO of Cellumen. "As a result, we are spinning out our personalized medicine unit to better address the market demands. Cernostics Pathology will focus on digital imaging pathology and personalized medicine using Tissue Systems Biology (TSB(TM)), which is CSB applied to tissues."
Sometimes, I can't help feeling that some people really haven't grasped the concept of systems biology.
Leave a comment